SurModics Stock News

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

Surmodics, Inc. (NASDAQ:SRDX ) Q2 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Tim Arens - SVP, Finance & CFO Gary Maharaj - President & CEO Conference Call Participant

SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q1 2022 Results - Earnings Call Transcript

Surmodics press release (SRDX): FQ1 Non-GAAP EPS of -$0.13.Revenue of $23M (+3.1% Y/Y).Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million vs

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Present at Sidoti & Company Virtual Investor Conference on January 19, 2022.

New York State Teachers Retirement System reduced its position in Surmodics, Inc. (NASDAQ:SRDX) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,326 shares of the companys stock after selling 500 shares during the quarter. New York []

Shares of Surmodics, Inc. (NASDAQ:SRDX) gapped up before the market opened on Tuesday . The stock had previously closed at $44.84, but opened at $47.67. Surmodics shares last traded at $45.99, with a volume of 2 shares. Separately, Needham & Company LLC dropped their price objective on Surmodics from $76.00 to $70.00 and set a []

Assenagon Asset Management S.A. lowered its stake in Surmodics, Inc. (NASDAQ:SRDX) by 2.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 103,586 shares of the companys stock after selling 2,230 shares during the period. Assenagon Asset Management S.A. owned approximately 0.75% of Surmodics worth []